Inozyme Pharma (INZY) Competitors

enGene (NASDAQ:ENGN) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Is ENGN or INZY more profitable?

enGene's return on equity of -16.69% beat Inozyme Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-16.69%	-14.27%
Inozyme Pharma	N/A	-88.42%	-57.02%

Do insiders and institutionals have more ownership in ENGN or INZY?

64.2% of enGene shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more volatility & risk, ENGN or INZY?

enGene has a beta of -0.61, indicating that its stock price is 161% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Does the MarketBeat Community prefer ENGN or INZY?

Inozyme Pharma received 41 more outperform votes than enGene when rated by MarketBeat users. However, 95.00% of users gave enGene an outperform vote while only 88.24% of users gave Inozyme Pharma an outperform vote.

Company	Underperform	Outperform
enGene	Outperform Votes 19 95.00%	Underperform Votes 1 5.00%
Inozyme Pharma	Outperform Votes 60 88.24%	Underperform Votes 8 11.76%

Which has stronger valuation & earnings, ENGN or INZY?

enGene is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$55.14M	-$1.52	-2.83
Inozyme Pharma	N/A	N/A	-$71.17M	-$1.63	-0.56

Does the media refer more to ENGN or INZY?

In the previous week, enGene had 3 more articles in the media than Inozyme Pharma. MarketBeat recorded 5 mentions for enGene and 2 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 1.61 beat enGene's score of 0.50 indicating that Inozyme Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inozyme Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer ENGN or INZY?

enGene currently has a consensus price target of $25.22, indicating a potential upside of 486.56%. Inozyme Pharma has a consensus price target of $14.56, indicating a potential upside of 1,482.13%. Given Inozyme Pharma's higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00
Inozyme Pharma	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

enGene beats Inozyme Pharma on 8 of the 15 factors compared between the two stocks.